Geneva, Sept. 23 -- International Clinical Trials Registry received information related to the study (NCT06919965) titled 'A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer' on April 2.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Janssen Research & Development, LLC
Condition:
Non-Muscle Invasive Bladder Neoplasms
Intervention:
Drug: TAR-210
Drug: Mitomycin C
Recruitment Status: Not recruiting
Phase: Phase 3
Date of First Enrollment: September 22, 2025
Target Sample Size: 220
Countries of Recruitment:
Isr...